Physician profile
James Allen Schmidt
NPI 1336243666
$12,294.03
in general payments reported to CMS, 2019-2025
53 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $1,972 · 2021: $2,616 · 2022: $1,441 · 2023: $1,485 · 2024: $1,633 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,299.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,702.03 | 2020-2025 | Vraylar, Qulipta, Synthroid |
| Amgen INC. | $1,075.87 | 2020-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $777.97 | 2019-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $648.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $564.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $532.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.20 | 2021-2025 | |
| Novo Nordisk INC | $375.80 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $344.00 | 2020-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.97 | 2019-2024 | Xifaxan |
| Allergan, INC. | $307.49 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $267.37 | 2019-2025 | Ztlido |
| Eisai INC. | $252.51 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.17 | 2019-2025 | Jardiance |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.